PT - JOURNAL ARTICLE AU - Cagigi, Alberto AU - Yu, Meng AU - Falck-Jones, Sara AU - Vangeti, Sindhu AU - Österberg, Björn AU - Åhlberg, Eric AU - Azizmohammadi, Lida AU - Falck-Jones, Ryan AU - Gubisch, Pia C AU - Ödemis, Mert AU - Ghafoor, Farangies AU - Lenart, Klara AU - Bell, Max AU - Johansson, Niclas AU - Albert, Jan AU - Sälde, Jörgen AU - Pettie, Deleah AU - Murphy, Michael AU - Carter, Lauren AU - King, Neil P AU - Ols, Sebastian AU - Färnert, Anna AU - Loré, Karin AU - Smed-Sörensen, Anna TI - Airway antibodies wane rapidly after COVID-19 but B cell memory is generated across disease severity AID - 10.1101/2020.11.25.20238592 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.25.20238592 4099 - http://medrxiv.org/content/early/2020/11/29/2020.11.25.20238592.short 4100 - http://medrxiv.org/content/early/2020/11/29/2020.11.25.20238592.full AB - Understanding immune responses following SARS-CoV-2 infection in relation to COVID-19 severity is critical to predicting the effects of long-term immunological memory on viral spread. Here we longitudinally assessed systemic and airway immune responses against SARS-CoV-2 in a well-characterized cohort of 147 infected individuals representing the full spectrum of COVID-19 severity; from asymptomatic infection to fatal disease. High systemic and airway antibody responses were elicited in patients with moderate to severe disease, and while systemic IgG levels were maintained after acute disease, airway IgG and IgA declined significantly. In contrast, individuals with mild symptoms showed significantly lower antibody responses but their levels of antigen-specific memory B cells were comparable with those observed in patients with moderate to severe disease. This suggests that antibodies in the airways may not be maintained at levels that prevent local virus entry upon re-exposure and therefore protection via activation of the memory B cell pool is critical.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill & Melinda Gates Foundation, the Knut and Alice Wallenberg Foundation through SciLifeLab and Karolinska Institutet.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Ethical Review Authority, and performed according to the Declaration of Helsinki. Reference: 2015/1949-31/4All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings os this study are available from the corresponding author on reasonable request.